All News

RheumNow Podcast square

Best Rheumatologists (7.19.2024)

d Jack Cush, MD

This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.

Read Article
eye.exam_.equip_.jpg

JAK Inhibitors Reduce Macular Degeneration

d Mepage Today

Insurance claims data showed that patients with autoimmune disorders who took Janus kinase (JAK) inhibitors had lower rates of age-related macular degeneration (AMD), hinting that the drugs might treat the common eye disease.

Read Article
Open Palm indicating pain

Geography of Arthritis-attributable Pain in the USA

d Jack Cush, MD

The journal Pain has shown geographic differences in arthritis-attributable pain, arthritis-related outcomes mostly clustered in the Deep South and Appalachia, while severe arthritis pain is more prevalent in the Southwest, Pacific Northwest, Georgia, Florida, and Maine.  

Read Article
trophy

Top 20 Best Rheumatology Hospitals - 2024

d Jack Cush, MD

Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 7th year in a row they have held this spot.

Read Article
PSS.scleroderma.arthritis.contractures

Updated EULAR Recommendations on the Treatment of Systemic Sclerosis

d Medscape

Medscape has published an overview to the 2024 updated recommendations for the treatment of systemic sclerosis (SSc) presented in Vienna at EULAR 2024 by Professor Francesco Del Galdo, MD, PhD on behalf of a 27 member task force.

Read Article
Enhance your clinical practice with insights from the EULAR 2024 Poster Hall Presentations, now on https://t.co/V10S4oVFsv. This year's conference showcases pivotal research in rheumatology. Visit https://t.co/gL38TVZRkM to stay at the forefront of medical innovation. https://t.co/cZontmAPTq

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Metrics Used by Rheumatologists in RA https://t.co/7Qr4cYvqp1 https://t.co/1FnyNpfhqi

Links:

Dr. John Cush RheumNow ( View Tweet)
Pain in RA: Different Drugs for Different Mechanisms https://t.co/pOETFkTIkS https://t.co/Vn5zgrYsKR

Links:

Dr. John Cush RheumNow ( View Tweet)
Top 20 Best Rheumatology Hospitals - 2024 Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 7th year in a row they have held this spot. https://t.co/ZHogsqVR5H https://t.co/45qm4Li4ii

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 478 CA pts Rx w. anti-PD-(L)1 Ab or anti-CTLA4 Ab - 28 (6%) had pre-existing Autoimmune Dz (AI). irAE (w/ checkpoint inhib) were higher w/ preexisting AI (57% vs 35%), but activity of AI was not related to irAEs occurrence. https://t.co/CHIdaH91qR https://t.co/XuaLk4D205

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective cohort study from 474 055 participants in UK Biobank, finds long-term exposure to air pollutants, NO2 etc, assoc w/ a 19% to 47% increased risk incident psoriasis. Air pollution and genetic predisposition also significantly incr incident PsO https://t.co/ogX81ybU3l https://t.co/Mvd6tAj2j6

Links:

Dr. John Cush RheumNow ( View Tweet)
IL-17 inhibitor Brodalumab is not often talked about, but its approved for PsO & PsA. German study of 227 PsO w/ 37 PsA pts Rx w/ BRO - good, rapid response by 3 mos. 1 year drug survival rate was 76.2%, (mean discontinuation=8.3 mos. https://t.co/4byFoc96Zs https://t.co/sPomX0s8aa

Links:

Dr. John Cush RheumNow ( View Tweet)
192 RA pts on MTX: GI Sxs studied w/ MISS (MTX intolerance severity score). GI intolerance seen in 56%, Nausea & pain post-MTX most common. More in afro-descendants, w/ FM, Steroids, or JAKi. MISS results unrelated to Route, Gi Dz, age, MTX dose https://t.co/EROmZQo1Zs https://t.co/SOMzzXXj0b

Links:

Dr. John Cush RheumNow ( View Tweet)
Updated EULAR Recommendations on the Treatment of Systemic Sclerosis Medscape has published an overview to the 2024 updated recommendations for the treatment of SSc presented in Vienna at EULAR 2024. https://t.co/U0usOgajFQ https://t.co/Hos3mu7rVE

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Comments on CMS Proposed 2025 Physician Payment Rule The American College of Rheumatology (ACR) shared the following initial reaction to the proposed CY 2025 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program rule. https://t.co/l5aUWiCtQE https://t.co/7jQdouVRbm

Links:

Dr. John Cush RheumNow ( View Tweet)
Febuxostat is assoc w/ a reduced risk of kidney events and slower decline in eGFR. Metanalysis of 16 RCTs, shows febuxostat w/a reduced risk of kidney events (RR=0.56) & slower decline in eGFR; & reduced urine albumin to creatinine ratio https://t.co/GQ8UopbA88 https://t.co/WQskc1yZ02

Links:

Dr. John Cush RheumNow ( View Tweet)
IRIS-RA, a failed phase 2 study of Nipocalimab, an anti-FcRn mAb severe active RA not responding to TNFi. 53 seropos. RA pts did not achieve primary endpt of better DAS28-CRP at Wk 12 (but Nipo was numerically better & signif lowered RF, CCP, but not CRP) https://t.co/52HLsfpKLS https://t.co/eEifXA6MpP

Links:

Dr. John Cush RheumNow ( View Tweet)
Pathogenesis of Autoimmune Liver Disease (ALDs) ALDs, including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), are complex conditions involving the liver's immune-mediated damage https://t.co/acgwwglKve https://t.co/ZDpF1VhBlc

Links:

Dr. John Cush RheumNow ( View Tweet)
Medscape review of new Gout research from EULAR 2024 - Phase 3 trial program for SEL-212 - Safety of SEL-212 - New Selective URAT1 Inhibitors - ruzinurad & AR882 https://t.co/szVRO2sqpu https://t.co/B9LcdpeCGd

Links:

Dr. John Cush RheumNow ( View Tweet)
Recurrent chronic monarthritis treatment with microwave ablation (MWA). 22 pts, 24 knees requiring median 5 IA aspirations in the last 6 mos.(total 129) decreased to 7 total in 6 mos post MWA ((0.89 vs 0.03/mo, P < 0.001). No complication. https://t.co/M2N0eFFKvL https://t.co/EOKUfudtSS

Links:

Dr. John Cush RheumNow ( View Tweet)
×